Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-9563 in Mild Hypertension
NCT07117474Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Antisense DNA, MicroRNA (miRNA), Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-9563 in hypertension (HTN) (5 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoint: Adverse Events at Day 169. Started Dec 2024; status: completed.
02
Drugs
HRS-9563
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT07117474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117474.